Dexilant (dexlansoprazole) is the medication most likely to cause hypokalemia among the listed options
Among the medications listed, Dexilant (dexlansoprazole), a proton pump inhibitor (PPI), is the only one with documented evidence of causing hypokalemia. The FDA drug label explicitly lists hypokalemia as a postmarketing adverse reaction 1.
Evidence-Based Analysis
Dexilant (Dexlansoprazole) - Confirmed Risk
The FDA-approved drug label for Dexilant specifically identifies hypokalemia as a postmarketing adverse reaction 1. This represents the highest quality evidence available (regulatory drug labeling). PPIs as a class are recognized in cardiovascular guidelines as medications that can cause hypokalemia, along with other electrolyte disturbances including hypomagnesemia 2.
Clinical Implication: When prescribing Dexilant, particularly for prolonged periods (>12 weeks), monitor serum potassium levels, especially in patients with:
- Concurrent diuretic use
- Chronic kidney disease
- Concomitant medications that affect potassium (ACEIs, ARBs, potassium-sparing diuretics)
Other Medications - No Evidence of Hypokalemia Risk
Sinemet (levodopa/carbidopa): The FDA label does not list hypokalemia as an adverse effect 3. While levodopa has been associated with hyponatremia and SIADH 4, there is no documented association with potassium depletion.
Rameron (mirtazapine): No evidence in the provided literature links this antidepressant to hypokalemia.
Ebixa: Note that the evidence provided discusses elexacaftor/tezacaftor/ivacaftor (a cystic fibrosis medication) 5, not memantine (the actual drug marketed as Ebixa). Neither medication has documented hypokalemia risk.
Plavix (clopidogrel): No association with hypokalemia in available evidence.
Clexane (enoxaparin): This low-molecular-weight heparin has no documented effect on potassium levels.
Key Clinical Pitfalls
PPI Duration: The risk of electrolyte disturbances with PPIs increases with prolonged use. Guidelines recommend using the minimum effective dose and questioning continued necessity after 12 weeks 2.
Polypharmacy Context: In elderly patients on multiple medications, PPIs combined with diuretics (the most common cause of drug-induced hypokalemia 6, 7) significantly amplify hypokalemia risk.
Monitoring Strategy: For patients on Dexilant long-term, establish baseline electrolytes and recheck periodically, particularly if symptoms of hypokalemia develop (weakness, fatigue, arrhythmias).